WO2024061608A1 - Procédé d'inhibition de la croissance de malassezia restricta - Google Patents

Procédé d'inhibition de la croissance de malassezia restricta Download PDF

Info

Publication number
WO2024061608A1
WO2024061608A1 PCT/EP2023/074228 EP2023074228W WO2024061608A1 WO 2024061608 A1 WO2024061608 A1 WO 2024061608A1 EP 2023074228 W EP2023074228 W EP 2023074228W WO 2024061608 A1 WO2024061608 A1 WO 2024061608A1
Authority
WO
WIPO (PCT)
Prior art keywords
glycine
composition
growth
microbes
weight
Prior art date
Application number
PCT/EP2023/074228
Other languages
English (en)
Inventor
Mingming PU
Zongxiu WANG
Original Assignee
Unilever Ip Holdings B.V.
Unilever Global Ip Limited
Conopco, Inc., D/B/A Unilever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Ip Holdings B.V., Unilever Global Ip Limited, Conopco, Inc., D/B/A Unilever filed Critical Unilever Ip Holdings B.V.
Publication of WO2024061608A1 publication Critical patent/WO2024061608A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Definitions

  • the present invention relates to method for microbiome balancing on an external surface of a human body, preferably on human skin or scalp, more preferably on scalp.
  • the invention relates to the use of glycine or a composition comprising a glycine for inhibiting the growth of harmful microbes which is Malassezia restricta.
  • the invention also relates to the use of glycine or a composition comprising a glycine on microbiome balancing on an external surface of a human body.
  • Microbes e.g. bacteria, fungi, viruses, protozoa and mites are often found to be present on surfaces such as fabrics, hard surfaces and skin.
  • Microbiome of a surface refers to this entire population of microbes that are present on a surface. Some of the microbes present on the surface considered to be beneficial whereas some of the other microbes that co-habits with the good microbes are detrimental in nature.
  • the scalp microbiome has recently become the focus of some attention for a potential causative role in dandruff progression.
  • the major fungal/bacterial species present on the scalp namely Malassezia restricta, Malassezia globosa, Cutibacterium acnes, Staphylococcus epidermidis and Staphylococcus capitis.
  • the lipophilic yeast Malasssezia restricta is known associated with dandruff condition.
  • Antifungals, such as zinc pyrithione, piroctone olamine, and selenium sulfide, have been demonstrated to be effective anti-dandruff agents by reducing the growth of Malassezia on scalp.
  • Staphylococcus and Cutibacterium are the most abundant bacteria genera across both healthy and dandruff scalps. However, at species level, Staphylococcus capitis is reported to be positively associated with dandruff conditions, while Staphylococcus epidermidis and Cutibacterium acnes, are considered as commensal bacteria, which are is positively associated with non-dandruff scalp conditions in terms of relative or absolute abundance.
  • Antimicrobial compositions are commonly used by individuals to eliminate or reduce the number of harmful microbes.
  • broad-spectrum antimicrobial composition such as zinc pyrithione, may also kills or inhibit the microbes which are beneficial.
  • glycine or a composition comprising glycine at certain level can inhibit the growth of Malassezia restricta when applied on an external surface of a human body, while having no inhibition effect on the commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes.
  • the present invention is directed to use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • the present invention is directed to use of of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for microbiome balancing, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for ensuring the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes while protecting the surface against harmful microbes which is Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • the present invention is directed to glycine or a composition comprising glycine for use in inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • the present inventio is directed to glycine or a composition comprising glycine for use in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • any feature of one aspect of the present invention may be utilized in any other aspect of the invention.
  • the word “comprising” is intended to mean “including” but not necessarily “consisting of or “composed of.” In other words, the listed steps or options need not be exhaustive. It is noted that the examples given in the description below are intended to clarify the invention and are not intended to limit the invention to those examples per se. Similarly, all percentages are weight/weight percentages unless otherwise indicated. Except in the operating and comparative examples, or where otherwise explicitly indicated, all numbers in this description and claims indicating amounts of material or conditions of reaction, physical properties of materials and/or use are to be understood as modified by the word "about”.
  • Numerical ranges expressed in the format “from x to y” are understood to include x and y. When for a specific feature multiple preferred ranges are described in the format “from x to y", it is understood that all ranges combining the different endpoints are also contemplated.
  • the indefinite article “a” or “an” and its corresponding definite article “the” means at least one, or one or more, unless specified otherwise.
  • the various features of the present invention referred to in individual sections above apply, as appropriate, to other sections mutatis mutandis. Consequently, features specified in one section may be combined with features specified in other sections as appropriate. Any section headings are added for convenience only and are not intended to limit the disclosure in any way.
  • “Hair care composition”, as used herein, is meant to include a composition for topical application to hair and/or scalp of mammals, especially humans. Such a composition may be generally classified as leave-on or rinse off, and includes any product applied to a human body for also improving appearance, cleansing, odor control or general aesthetics.
  • the composition of the present invention can be in the form of a liquid, lotion, cream, foam, scrub, gel, or bar. Non-limiting examples of such compositions include leave-on hair lotions, creams, and rinse-off shampoos, conditioners, shower gels, or toilet bar.
  • a microbe can be described as a tiny living organism, such as bacterium, fungus, virus protozoan, or mite.
  • a microbiome on a surface refers collectively to all the microbes on the surface. In other words, a microbiome is a community of microbes.
  • microbiome balancing means selectively eliminating/killing/reducing the microbes considered to be harmful existing on a surface whereas keeping the microbes considered to be beneficial substantially at the same level or even increasing the number of microbes which are considered to be beneficial.
  • Malassezia restricta (M. restricta), which a lipophilic yeast and one of the most abundant Malassezia species of the human skin microbiota. M. restricts is considered an opportunistic pathogen associated with skin disorders, such as seborrheic dermatitis and dandruff.
  • At least one of the microbes considered to be beneficial is Staphylococcus epidermidis (S. epidermidis).
  • S. epidermidis is reported to be a beneficial bacterium that participates in the maintenance of skin health. It is a kind of normal microbe which is likely to be involved in competitive exclusion of pathogens. It is thus an indication of microbiome status of the surface. The increase and maintenance of S. epidermidis is an important route to maintain the composition of healthy microbiome.
  • At least one of the microbes considered to be beneficial is Cutibacterium acnes (C. ances). It is one or the main bacterial species that have been identified on the healthy scalp.
  • the present invention relates to the use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body.
  • the surface is preferably human skin, for example, a surface like the hands, face, body or scalp. More preferably, the surface is scalp.
  • Microbiome balancing is obtained by selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from S. epidermidis and C. acnes.
  • the present invention relates to use of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body.
  • the surface is preferably human skin, for example, a surface like the hands, face, body or scalp. More preferably, the surface is scalp.
  • glycine or the composition in accordance with the present invention has less impact on the growth of microbes of other Malassezia genus, such as Malassezia furfur.
  • the use of glycine or the composition in accordance with the present invention has no inhibition effect on the growth of Malassezia furfur.
  • Glycine is an amino acid which is essential in the production of collagen, a protein that gives structure to bones, skin, muscles, and connective tissues. It is the simplest stable amino acid, with the chemical formula NH2-CH2-COOH.
  • Amino acids are usually considered as nutrient source for both microorganisms and human. It is surprisingly to be found that glycine or the composition comprising glycine at certain level can inhibit the growth of Malassezia restricta when applied on a surface. However such use has no inhibition effect on the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes. Therefore, such use can provide microbiome balancing, selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from S. epidermidis and C. acnes.
  • composition of the present invention comprises at least 0.04% of glycine, preferably at least 0.1% of glycine, more preferably at least 0.15% of glycine by weight of the composition.
  • the composition comprises from 0.04 to 10% of glycine, preferably from 0.1% to 5% of glycine, more preferably from 0.15 to 2%, furthermore preferably from 0.2 to 2% by weight of the total composition and including all ranges subsumed therein.
  • the minium preferred concentration of the glycine can be higher. It is generally preferred that the concentration of the glycine in the composition in the use according to the present invention is equal or higher than the optimal concentrations in the working composition, because in many typical applications, the composition is either used pure or is diluted to form the working composition.
  • the lather produced typically is a 50 wt% dilution of the original composition. Similary, in hair wash , body wash situations, liquids soap or bars are typically diluted until about 8 wt% to 10wt% in water, corresponding to an approximately tenfould dilution of the product.
  • the concentration of the glycine in the composition is preferably such that, when the composition is diluted or dissolved with a suitable medium before or during use, the concentration in the diluted or dissolved mixture is still sufficient to provides microbiome balancing benefits on an external surface of a human body.
  • the composition is preferably a personal care composition.
  • a personal care composition is a composition for the treatment, cleaning, caring or conditioning of the person.
  • the foregoing includes, but not limited to, chemicals, compositions, products, or combinations thereof relating to or having use or application in the treatment, cleansing or conditioning of the person (including in particular the skin, hair, scalp and oral cavity), and the manufacture of all the foregoing.
  • Examples of a personal care composition include but not limited to leave-on skin lotions and creams, shampoos, conditioners, shower gels, soap bars, antiperspirants, deodorants, shave creams, depilatories, lipsticks, foundations, mascara, sunless tanners or sunscreen lotions.
  • the composition is leave-on personal care composition.
  • Preferred personal care compositions for use in the invention include rinse-off or leave- on hair or scalp care compositions such as shampoos, conditioners, creams, lotions, gels, serums, mousses or oils.
  • Leave-on hair or scalp care compositions are preferred, such as lotions, serums, oils, which are intended for topical application to the hair or scalp.
  • compositions for use in the invention will generally include a cosmetically acceptable carrier.
  • Cosmetically acceptable means that the carrier is suitable for topical application to the skin, has good aesthetic properties, is compatible with any other ingredients, and will not cause any safety or toxicity concerns.
  • the carrier may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase or a mixture thereof, and may be in the form of an emulsion.
  • Emulsions can have a range of consistencies including thin lotions (which may also be suitable for spray or aerosol delivery), creamy lotions, light creams and heavy creams.
  • compositions for use in the invention may also be formulated in a single-phase carrier such as a hydrophobic or hydrophilic liquid.
  • Suitable hydrophobic liquid carriers include liquid polyorganosiloxanes, mineral oils, hydrogenated polyisobutene, polydecene, paraffins and isoparaffins of at least 10 carbon atoms, aliphatic or aromatic ester oils (such as isopropyl myristate, lauryl myristate, isopropyl palmitate, diisopropyl sebacate, diisopropyl adipate and C12 to C15 alkyl benzoates), polyglycol ethers (such as polyglycol butanol ethers) and mixtures thereof.
  • Suitable hydrophilic liquid carriers include water, monohydric or polyhydric aliphatic alcohols having 2 to 8, preferably 2 or 3 carbon atoms (such as ethanol and isopropanol, oligoglycol ethers having 2 to 5 repeat units (such as dipropylene glycol) and mixtures thereof.
  • a particularly preferred carrier is water.
  • Liquid form compositions for use in the invention may be thickened, for example using one or more water soluble or colloidally water soluble polymeric thickening agents.
  • composition for use in the invention comprises a thickening agent.
  • Suitable water soluble or colloidally water soluble polymeric thickening agents include hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyquaternium-10, carrageenan, guar gum, hydroxypropyl guar gum, xanthan gum, polyvinylalcohol, acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers, crosslinked polyacrylate polymers and polyacrylamide polymers.
  • the composition for use in the invention may additionally comprise a conditioning agent to provide conditioning benefit.
  • the composition comprises discrete dispersed droplets of a water-insoluble conditioning agent, which has a mean droplet diameter (D3,2) of less than 15 microns, preferably less than 10 microns, more preferably less than 5 microns, most preferably less than 3 microns.
  • the mean droplet diameter (D3,2) of a water-insoluble conditioning agent may be measured by means of a laser light scattering technique, for example using a 2600D Particle Sizer from Malvern Instruments.
  • the water-insoluble conditioning agent may include non-silicone conditioning agent comprising non-silicone oily or fatty materials such as hydrocarbon oils, fatty esters and mixtures thereof.
  • the water-insoluble conditioning agent is emulsified silicone oil.
  • Suitable silicones include polydiorganosiloxanes, in particular polydimethylsiloxanes which have the CTFA designation dimethicone.
  • polydimethyl siloxanes having hydroxyl end groups which have the CTFA designation dimethiconol.
  • silicone gums having a slight degree of cross-linking, as are described for example in WO 96/31188.
  • the silicone oil comprises dimethicone, dimethiconol or a mixture thereof.
  • Suitable emulsified silicones included in the compositions for use in this invention are available as pre-formed silicone emulsions from suppliers of silicones such as Dow Corning and GE silicones. The use of such pre-formed silicone emulsion is preferred for ease of processing and control of silicone particle size.
  • Such pre-formed silicone emulsions will typically additionally comprise a suitable emulsifier, and may be prepared by a chemical emulsification process such as emulsion polymerisation, or by mechanical emulsification using a high shear mixer.
  • suitable pre-formed silicone emulsions include DC1785, DC1788, DC7128, all available from Dow Corning. These are emulsions of dimethiconol/dimethicone.
  • silicones which may be used are functionalized silicones such as amino functional silicones, meaning a silicone containing at least one primary, secondary or tertiary amine group, or a quaternary ammonium group.
  • suitable amino functional silicones include polysiloxanes having the CTFA designation “amodimethicone.”
  • the water-insoluble conditioning agent is generally present in the composition for use in this invention in an amount from 0.05 to 15%, preferably from 0.1 to 10%, more preferably from 0.5 to 8%, most preferably from 1 to 5%, based on total weight of the composition.
  • the pH of the composition for use according to the present invention is preferably equal to or higher than 4.0, more preferably in the range of 5.0 to 10.0.
  • Oils and lotions for use in the invention typically have an oil phase containing at one or more cosmetically acceptable fatty materials which may be liquid or solid at room temperature (25°C).
  • Lotions are typically aqueous emulsions having an aqueous phase in addition to the oil phase.
  • Suitable cosmetically acceptable fatty materials include naturally derived oils (such as sunflower oil, borage oil, soybean oil, castor oil, olive oil and almond oil); esters of monoalcohols or of polyols with monocarboxylic or polycarboxylic acids, at least one of the alcohols and/or acids comprising at least one hydrocarbon-based chain containing at least 6 carbon atoms (such as octyl palmitate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, hexyl laurate, isohexyl laurate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, dihexyldecyl adipate, lauryl lactate, myristyl lactate, cetyl lactate, oleyl stearate, oleyl ole
  • the aqueous phase of lotions for use in the invention may also include one or more organic liquids that are miscible with water at room temperature (25°C).
  • exemplary water-miscible organic liquids include monohydric and polyhydric alcohols and derivatives thereof such as C2-C6 alkanols (such as ethanol and isopropanol); C2-C10 glycols and polyols (such as glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, and diethylene glycol); C3- C16 glycol ethers (such as mono-, di-, or tripropylene glycol (C1-C4) alkyl ethers and mono-, di-, or triethylene glycol (C1-C4) alkyl ethers) and polyethylene glycol having 2 to 12 oxyethylene units.
  • C2-C6 alkanols such as ethanol and isopropan
  • Lotions for use in the invention may also include surface active ingredients, such as emulsifiers and solubilizers, to enable two or more immiscible components to be combined homogeneously and to help stabilize the composition.
  • Emulsifiers that may be used to form O/W or W/O emulsions include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, PEG-20 sorbitan isostearate, polyglyceryl-3- diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polyglyceryl-4 oleate/PEG-8 propylene glycol cocoate, polyglyceryl-2 dipolyhydroxystearate, PEG-30 dipolyhydroxystearate, oleamide DEA, TEA myristate, TEA stearate
  • Compositions for use in the invention may include additional actives for improving the physical and/or aesthetic characteristics of the scalp and/or the hair.
  • additional actives for improving the physical and/or aesthetic characteristics of the scalp and/or the hair.
  • examples include amino acids, vitamins, minerals and/or antioxidants, emollients, humectants, sunscreens, anti-irritants, exfoliating agents, botanical extracts (such as pomegranate, white birch, green tea, chamomile and licorice extracts) and mixtures thereof.
  • Compositions for use in the invention may include additional functional ingredients for improving the physical and/or aesthetic characteristics of the composition per se.
  • additional functional ingredients include inorganic pigments (such as titanium oxide, zirconium oxide, cerium oxide, zinc oxide, iron oxide, chromium oxide, manganese violet, ultramarine blue, chromium hydrate and ferric blue); organic pigments (such as carbon black and the organic lakes of barium, strontium, calcium or aluminium); pearlescent agents (such as mica coated with titanium oxide and/or iron oxide); dyes, preservatives (such as disodium EDTA, benzyl alcohol, methylparaben, phenoxyethanol, propylparaben, ethylparaben, butylparaben and isobutylparaben); pH adjusters and fragrances (such as essential oils, flower oils, natural extracts from resins, gums, balsams, beans, mosses and other plants, as well as synthetic aromatic materials).
  • inorganic pigments such as titanium oxide,
  • Preservatives may also be incorporated into the composition for use in this invention to protect against the growth of potentially harmful microorganisms.
  • Suitable traditional preservatives include alkyl esters of parahydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds.
  • preservatives include, for examples, phenoxyethanol, sodium salicylate, methyl paraben, butyl paraben, propyl paraben, diazolidinyl urea, sodium dehydroacetate, benzyl alcohol, sodium benzoate, iodopropynyl butylcarbamate, caprylyl glycol, disodium EDTA or mixtures thereof.
  • the preservative is sodium benzoate, phenoxyethanol, sodium salicylate or a mixture thereof.
  • Preservatives are preferably employed in amounts ranging from 0.01 to 2% by weight of the composition.
  • the composition for use in the invention comprises a cosmetic ingredient.
  • the cosmetic ingredient is selected from the group consisting of a silicone, an antibacterial agent other than antidandruff agents, a foam booster, a perfume, encapsulates (for example encapsulated fragrance) a dye, a colouring agent, a pigment, a preservative, a thickener, a protein, a phosphate ester, a buffering agent, a pH adjusting agent, a pearlescer (for example; mica, titanium dioxide, titanium dioxide coated mica, ethylene glycol distearate (INCI glycol distearate)) and/or opacifier, a viscosity modifier, an emollient, a sunscreen, an emulsifier, a sensate active (for example menthol and menthol derivatives), vitamins, mineral oils, essential oils, lipids, natural actives, glycerin, natural hair nutrients such as botanical extracts, fruit extracts, sugar derivatives and amino acids, micro
  • the composition for use in the present invention includes from 0.01 to 20 wt% of the at least one cosmetic ingredient, more preferably from 0.05 to 10 wt%, still more preferably from 0.075 to 7.5 wt% and most preferably, from 0.1 to 5 wt% of the at least one cosmetic ingredient, by weight of the total composition.
  • the present invention provides for use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff.
  • the use is preferably non-therapeutic in nature, more preferably cosmetic in nature.
  • the present invention provides for use of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • Such microbiome balancing can be used for the treatment of dandruff.
  • the use is preferably non-therapeutic in nature, more preferably cosmetic in nature.
  • the present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff.
  • the method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
  • the present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for microbiome balancing, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • microbiome balancing can be used for the treatment of dandruff.
  • the method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
  • the present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for ensuring the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes while protecting the surface against harmful microbes which is Malassezia restricta, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • the method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
  • the present invention provides for glycine or a composition comprising glycine for use in inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff.
  • the present invention provides for glycine or a composition comprising glycine for use in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • Such microbiome balancing can be used for the treatment of dandruff.
  • the present invention provides for glycine or a composition comprising glycine for use as a medicament. It provides for glycine or a composition comprising glycine for use as a medication for inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • glycine or a composition comprising glycine for use as a medication for microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
  • the composition is suitably applied to the hair or scalp and massaged into the surface of the scalp.
  • an amount corresponding to about 1 to 15 ml of the composition per application is applied uniformly over the area of treatment daily or at least once a week over a time interval of at least 7 (seven) days, preferably at least 28 days, more preferably at least 30 (thirty) days.
  • the invention will be further illustrated by the following, non-limiting Examples.
  • M. restricta (CBS 7877) was revitalized on modified Leeming and Notman agar (mLNA) plates from -80 °C freezer by incubation at 32 °C for 5 days.
  • the microbe was further cultured in 20ml of liquid growth medium modified Leeming and Notman broth (mLNB) at 32 °C for 48 hrs with shaking. Then, 1ml of the first broth culture was transferred into 9 ml of fresh mLNB and incubated at 32 °C for 48 hrs with shaking and ready to use.
  • mLNB liquid growth medium modified Leeming and Notman broth
  • CBS 1878 Malassezia. furfur (CBS 1878) was revitalized on Pityrosporum Broth (PB) agar by incubation at 32 °C for 2 days. The microbe was further cultured in 20) ml of liquid growth medium PB broth at 32 °C for 48 hrs with shaking. Then, 1ml of the first broth culture is transferred into 9ml of fresh PB and incubated at 32 °C for 48 hrs with shaking and ready to use.
  • PB Pityrosporum Broth
  • S. epidermidis (ATCC_12228) was revitalized on Tryptic soy agar (TSA) by incubation at 37 °C overnight.
  • TSA Tryptic soy agar
  • the microbe was further cultured in 20 ml of liquid growth medium Tryptic soy broth (TSB) at 37 °C overnight and ready to use.
  • TSA Tryptic soy agar
  • C. acnes (ATCC_6919) were revitalized on TSA plates by incubation at 37 °C for 5 days anaerobically.
  • the microbe was further cultured in 20 ml of liquid growth medium TSB at 37 °C for 4 days anaerobically and ready to use.
  • OD optical density
  • samples 1 to 5 comprising glycine at a level consistent with the present invention were able to selectively inhibit the growth of harmful microbes (/W. restricta) while having no inhibition effect on the growth of beneficial microbes (S.epidermidis and C. acnes). Furthermore, the result in table above indicates that the using of composition comprising glycine at a level consistent with the present invention has less impact on the number of other Malassezia genus, such as Malassezia furfur (M. furfur).
  • M. restricta Malassezia restricta
  • M. restricta growth was monitored with or without adding 0.5% of different amino acids by culturing M. restricta in mLNB liquid medium for 3 days.
  • the pH of the solutions was all adjusted to the same level of pH 5.5. The same protocol was used to observe the growth of the microbes.
  • sample 6 comprising glycine at a level consistent with the present invention were able to inhibit the growth of harmful microbes ⁇ M. restricta), while the samples comprising other amino acids cannot.
  • compositions comprising glycine at a level consistent with the present invention were able to inhibit the growth of harmful microbes (M. restricta).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation de glycine ou d'une composition comprenant de la glycine dans l'inhibition de la croissance de Malassezia restricta lorsqu'elle est appliquée sur une surface externe d'un corps humain ; la composition comprenant au moins 0,04 % de glycine en poids de la composition. Elle concerne également l'utilisation de glycine ou d'une composition comprenant de la glycine dans l'équilibrage du microbiome sur une surface, des moyens d'équilibrage réduisant sélectivement le nombre de microbes nocifs qui est Malassezia restricta, tout en n'ayant aucun effet de réduction sur le nombre de microbes commensaux choisis parmi Staphylococcus epidermidis et Cutibacterium acnes ; la composition comprenant au moins 0,04 % de glycine en poids de la composition.
PCT/EP2023/074228 2022-09-20 2023-09-05 Procédé d'inhibition de la croissance de malassezia restricta WO2024061608A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2022119767 2022-09-20
CNPCT/CN2022/119767 2022-09-20
EP22203435.7 2022-10-25
EP22203435 2022-10-25

Publications (1)

Publication Number Publication Date
WO2024061608A1 true WO2024061608A1 (fr) 2024-03-28

Family

ID=87930093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/074228 WO2024061608A1 (fr) 2022-09-20 2023-09-05 Procédé d'inhibition de la croissance de malassezia restricta

Country Status (1)

Country Link
WO (1) WO2024061608A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031188A1 (fr) 1995-04-06 1996-10-10 Unilever Plc Compositions pour traitement capillaire
KR20090099163A (ko) * 2008-03-17 2009-09-22 장경선 블랙 머드를 함유하는 샴푸 조성물
US20110077193A1 (en) * 2007-01-01 2011-03-31 Bioderm Research Artemisinin Derivatives with Natural Amino Acids, Peptides, and Amino Sugars for the Treatment of Infection and Topical Condition in Mammals
CN111643433A (zh) * 2020-07-27 2020-09-11 广州市柏亚化妆品有限公司 一种控油去屑洗发组合物
WO2020244898A1 (fr) * 2019-06-06 2020-12-10 Unilever N.V. Composition topique destinée à restaurer la diversité microbienne d'une peau sensible au traitement

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031188A1 (fr) 1995-04-06 1996-10-10 Unilever Plc Compositions pour traitement capillaire
US20110077193A1 (en) * 2007-01-01 2011-03-31 Bioderm Research Artemisinin Derivatives with Natural Amino Acids, Peptides, and Amino Sugars for the Treatment of Infection and Topical Condition in Mammals
KR20090099163A (ko) * 2008-03-17 2009-09-22 장경선 블랙 머드를 함유하는 샴푸 조성물
WO2020244898A1 (fr) * 2019-06-06 2020-12-10 Unilever N.V. Composition topique destinée à restaurer la diversité microbienne d'une peau sensible au traitement
CN111643433A (zh) * 2020-07-27 2020-09-11 广州市柏亚化妆品有限公司 一种控油去屑洗发组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURAI T. ET AL: "Differentiation of Malassezia furfur and Malassezia sympodialis by glycine utilization . Unterscheidung von Malassezia furfur und Malassezia sympodialis mittels Glycin-Verwertung", vol. 45, no. 5-6, 1 June 2002 (2002-06-01), GB, pages 180 - 183, XP093037259, ISSN: 0933-7407, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full/10.1046/j.1439-0507.2002.00757.x> [retrieved on 20230412], DOI: 10.1046/j.1439-0507.2002.00757.x *

Similar Documents

Publication Publication Date Title
JP4418976B2 (ja) 防腐殺菌剤及び化粧料組成物
JP7286907B2 (ja) 局所用組成物
US11298312B2 (en) Composition comprising niacinamide and picolinamide
JP2003081761A (ja) 乳化組成物
JP2007039340A (ja) 防腐殺菌剤及び皮膚外用組成物
JP5039359B2 (ja) 防腐殺菌剤及び皮膚外用組成物
JP2007001947A (ja) 化粧料組成物
WO2015123512A1 (fr) Efficacité antimicrobienne d&#39;un mélange d&#39;huile d&#39;origan et d&#39;acide caprylique
US9943477B2 (en) Emulsion compositions containing a novel preservative system
WO2022096258A1 (fr) Utilisation de glycérine pour inhiber la croissance de microbes
JP5264829B2 (ja) 防腐殺菌剤及び化粧料組成物
WO2024061608A1 (fr) Procédé d&#39;inhibition de la croissance de malassezia restricta
WO2021132019A1 (fr) Agent pour améliorer l&#39;équilibre de la flore résidente cutanée
WO2024104742A1 (fr) Procédé d&#39;inhibition de croissance de microbes
CA3181110A1 (fr) Composition antimicrobienne pour lutter contre les mauvaises odeurs
JP7343089B2 (ja) 保存増強剤
EP3485869B1 (fr) Utilisation de phytantriol comme agent antimicrobien dans la conservation d&#39;une composition
JP2004067626A (ja) 外用剤組成物
WO2019007790A1 (fr) Nouvelle utilisation
CN117941682A (zh) 抗微生物组合物
KR20230074223A (ko) 에필로비움 플레이쉐리 추출물의 신규 용도
US20230301889A1 (en) Method of preventing or reducing hair fall
EA040067B1 (ru) Мононитрат моноацетата пропандиола
WO2010004016A1 (fr) Utilisation de phénoxyalkylamines dans des compositions cosmétiques et/ou dermatologiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23764942

Country of ref document: EP

Kind code of ref document: A1